BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Selinexor readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Selinexor\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04442022-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Selinexor\, phase 2/3.\nStudy: A Study of Rituximab-Gemcitabine
 -Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With
  Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04442022
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06559553-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT06559553)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: "Selinexor+Pegaspargase+Dexameth
 asone"in Ⅰ/Ⅱ NKTCL\nEstimated primary completion: 1 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06559553
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822972-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2 readout est. (NCT06822972)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: HCMT/MM2401: Ph
 2 Study of Selinexor + Bispecific Antibody for RRMM\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06822972
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02436707-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Selinexor: Phase 2 readout est. (NCT02436707)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Novel Combination Therapy in the T
 reatment of Relapsed and Refractory Aggressive B-Cell Lymphoma\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT02436707
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06517511-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Selinexor: Phase 2 readout est. (NCT06517511)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor in Combination With R-CH
 OP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
 \nEstimated primary completion: January 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06517511
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369739-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Selinexor: Phase 2/3 readout est. (NCT07369739)
DESCRIPTION:Selinexor\, phase 2/3.\nStudy: Golidocitinib Combined With Seli
 nexor for CAEBVD\nEstimated primary completion: 1 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07369739
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Selinexor\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor and
  Backbone Treatments of Multiple Myeloma Patients\nEstimated primary compl
 etion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 linexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02343042
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225310-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Selinexor: Phase 1 readout est. (NCT06225310)
DESCRIPTION:Selinexor\, phase 1\, Multiple Myeloma.\nStudy: A Trial of Seli
 nexor\, Ruxolitinib and Methylprednisolone\nEstimated primary completion: 
 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/selinex
 or#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6225310
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02835222-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270418
DTEND;VALUE=DATE:20270419
SUMMARY:Selinexor: Phase 2 readout est. (NCT02835222)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor With Combination With In
 duction/Consolidation Therapy in Acute Myeloid Leukemia Patients\nEstimate
 d primary completion: 18 April 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT02835222
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05333458-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Selinexor: Phase 2 readout est. (NCT05333458)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Testing Atezolizumab With Selinexo
 r in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma\, AXIOM Trial
 \nEstimated primary completion: 1 May 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05333458
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966154-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT06966154)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: A Phase Ib/II Clinical Study Eva
 luating the Safety and Efficacy of Tislelizumab in Combination With Golido
 citinib and Selinexor for the Treatment of R/R NKTCL\nEstimated primary co
 mpletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06966154
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Selinexor: Phase 2 readout est. (NCT05980806)
DESCRIPTION:Selinexor\, phase 2\, Myelofibrosis.\nStudy: A Study of Selinex
 or Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Mod
 erate Thrombocytopenia\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05980806
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03147885-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT03147885)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: Selinexor Plus Combination Chemo
 therapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma\nEs
 timated primary completion: 25 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03147885
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07094464-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Selinexor: Phase 1 readout est. (NCT07094464)
DESCRIPTION:Selinexor\, phase 1.\nStudy: Maintenance Therapy With Selinexor
  and Azacitidine in TP53 Mutant AML/MDS After Transplantation\nEstimated p
 rimary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/selinexor#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07094464
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05432804-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT05432804)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: Testing the Addition of an Anti-
 cancer Drug\, Selinexor\, to the Usual Chemotherapy Treatment (Temozolomid
 e) for Brain Tumors That Have Returned After Previous Treatment\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/selinexor#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05432804
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07479979-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT07479979)
DESCRIPTION:Selinexor\, phase 1/2\, Multiple Myeloma.\nStudy: Study of Seli
 nexor With Carfilzomib\, Isatuximab and Dexamethasone for Patients With Re
 lapsed and/or Refractory Multiple Myeloma\nEstimated primary completion: J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07479
 979
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06573138-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Selinexor: Phase 2 readout est. (NCT06573138)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor\, Anti-PD-1 Antibody Plu
 s Golidocitinib in R/R NKTCL\nEstimated primary completion: 1 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06573138
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06573151-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Selinexor: Phase 2 readout est. (NCT06573151)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor\, Anti-PD-1 Antibody and
  P-GemOx Regimen in R/R NKTCL\nEstimated primary completion: 1 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06573151
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204041-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Selinexor: Phase 2 readout est. (NCT07204041)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Efficacy and Safety of XTD Regimen
  (Selinexor\, Thalidomide and Dexamethasone) in Adult Patients With Relaps
 ed/Refractory LCH\nEstimated primary completion: 1 August 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07204041
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191431-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Selinexor: Phase na readout est. (NCT07191431)
DESCRIPTION:Selinexor\, phase na.\nStudy: A Clinical Study on the Efficacy 
 and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temo
 zolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refra
 ctory Primary or Secondary Central Nervous System Lymphoma（SELINA）\nEs
 timated primary completion: 2 September 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07191431
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099003-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT05099003)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: A Study of the Drug Selinexor Wi
 th Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Po
 ntine (DIPG) Glioma and High-Grade Glioma (HGG)\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05099003
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06613035-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Selinexor: Phase 3 readout est. (NCT06613035)
DESCRIPTION:Selinexor\, phase 3.\nStudy: Twice-per-weekSelinexor\, 2 Days M
 elphalan\nEstimated primary completion: 30 September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06613035
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07632170-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Selinexor: Phase na readout est. (NCT07632170)
DESCRIPTION:Selinexor\, phase na.\nStudy: The Efficacy and Safety of Selini
 sole Combined With Azacitidine and Venetoclax in the Treatment of Newly Di
 agnosed High-risk Myeloid Tumors With TP53 Mutations\nEstimated primary co
 mpletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07632170
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035745-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT05035745)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: Selinexor & Talazoparib in Advan
 ced Refractory Solid Tumors\; Advanced/Metastatic Triple Negative Breast C
 ancer (START)\nEstimated primary completion: November 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05035745
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172412-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selinexor: Phase 2 readout est. (NCT07172412)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Open-Label\, Biomarker-Integrated 
 Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung
  Cancer\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07172412
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selinexor: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Selinexor\, phase 3\, Multiple Myeloma.\nStudy: Study Assessing
  Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Availa
 ble Therapies in Adult Participants With Relapsed or Refractory Multiple M
 yeloma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405255-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Selinexor: Phase 2 readout est. (NCT07405255)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Zillion: Zanubrutinib Combined Wit
 h Chemotherapy for Newly Diagnosed CNS Lymphoma\nEstimated primary complet
 ion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07405255
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07437170-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selinexor: Phase 2 readout est. (NCT07437170)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor Combined With Induction 
 Chemotherapy for Children With NUP98-positive AML\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07437170
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554482-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Selinexor: Phase 2 readout est. (NCT07554482)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor Combined With Reduced-Do
 se Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07554482
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706959-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT07706959)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: New Genotype-guided Treatment in
  Newly Diagnosed PTCL\nEstimated primary completion: January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07706959
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04414475-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Selinexor: Phase 2 readout est. (NCT04414475)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: A Study of Seli
 nexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple M
 yeloma (MM)\, Seli and Bortezomib + LDD in Triple-class Refractory MM.\nEs
 timated primary completion: January 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04414475
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06744894-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Selinexor: Phase 2 readout est. (NCT06744894)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: SIL as Maintena
 nce Therapy in Multiple Myeloma\nEstimated primary completion: 1 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06744894
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265545-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Selinexor: Phase na readout est. (NCT06265545)
DESCRIPTION:Selinexor\, phase na.\nStudy: Multicenter\, Platform-type Clini
 cal Study of Refractory/Recurrent Acute Myeloid Leukemia\nEstimated primar
 y completion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/selinexor#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06265545
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Selinexor: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: A Study of Seli
 nexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide in P
 atients With Multiple Myeloma\nEstimated primary completion: February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743957-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Selinexor: Phase 2 readout est. (NCT07743957)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor\, Daratumumab\, and Dexa
 methasone (XDd) for Light-Chain Cardiac Amyloidosis\nEstimated primary com
 pletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07743957
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Selinexor: Phase 2 readout est. (NCT06813079)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Using Tumor Models to Determine Tr
 eatments\nEstimated primary completion: 17 February 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07574528-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280306
DTEND;VALUE=DATE:20280307
SUMMARY:Selinexor: Phase 2 readout est. (NCT07574528)
DESCRIPTION:Selinexor\, phase 2.\nStudy: A Phase II Study of Sintilimab\, P
 egaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stag
 e I/II Extranodal NK/T-Cell Lymphoma\nEstimated primary completion: 6 Marc
 h 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0757452
 8
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05530421-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280326
DTEND;VALUE=DATE:20280327
SUMMARY:Selinexor: Phase 2 readout est. (NCT05530421)
DESCRIPTION:Selinexor\, phase 2\, Multiple Myeloma.\nStudy: Selinexor\, Ven
 etoclax\, and Dexamethasone (XVenD) in t(11\;14)-Positive Relapsed/Refract
 ory Multiple Myeloma\nEstimated primary completion: 26 March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05530421
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779031-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT07779031)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: A Single-Arm\, Open Phase I Clin
 ical Study of Selinexor in Combination With Azacitidine for the Treatment 
 of High-Risk AML/MDS Patients After Allo-HSCT\nEstimated primary completio
 n: 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sel
 inexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07779031
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832227-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Selinexor: Phase 2 readout est. (NCT07832227)
DESCRIPTION:Selinexor\, phase 2\, Endometrial Cancer.\nStudy: Imlunestrant/
 Abemaciclib/Selinexor in Ovarian and Endometrial\nEstimated primary comple
 tion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07832227
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06552559-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT06552559)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: Selinexor With ICE Chemotherapy 
 in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma\
 nEstimated primary completion: 30 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06552559
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002099-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Selinexor: Phase 2 readout est. (NCT07002099)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Selinexor\, High-dose Methotrexate
 \, and Rituximab Combined With Radiotherapy for Newly Diagnosed\, Transpla
 nt-ineligible Patients With Central Nervous System Lymphoma: An Open-label
 \, Single-arm\, Multicenter Phase II Study\nEstimated primary completion: 
 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sel
 inexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07002099
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200102-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Selinexor: Phase 1 readout est. (NCT07200102)
DESCRIPTION:Selinexor\, phase 1\, Multiple Myeloma.\nStudy: Selinexor Maint
 enance Post CAR-T Cell Therapy for Multiple Myeloma\nEstimated primary com
 pletion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07200102
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05985161-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Selinexor: Phase 2 readout est. (NCT05985161)
DESCRIPTION:Selinexor\, phase 2.\nStudy: A Study of Selinexor in People Wit
 h Wilms Tumors and Other Solid Tumors\nEstimated primary completion: 1 Aug
 ust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/selinexor#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05985
 161
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276698-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Selinexor: Phase 2 readout est. (NCT07276698)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Clinical Study on Maintenance Ther
 apy With Selinexor Combined With Azacitidine After Allogeneic Hematopoieti
 c Stem Cell Transplantation for NK/T-cell Lymphoma\nEstimated primary comp
 letion: 30 December 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07276698
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07447817-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20300524
DTEND;VALUE=DATE:20300525
SUMMARY:Selinexor: Phase 2 readout est. (NCT07447817)
DESCRIPTION:Selinexor\, phase 2\, Myelofibrosis.\nStudy: Selinexor and Pacr
 itinib in JAK Inhibitor-naïve MF Patients With Cytopenias\nEstimated prim
 ary completion: 24 May 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07447817
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05983276-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20300828
DTEND;VALUE=DATE:20300829
SUMMARY:Selinexor: Phase 2 readout est. (NCT05983276)
DESCRIPTION:Selinexor\, phase 2.\nStudy: Decitabine and Selinexor in Combin
 ation to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Can
 cer\nEstimated primary completion: 28 August 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05983276
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239272-2266@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20340630
DTEND;VALUE=DATE:20340701
SUMMARY:Selinexor: Phase 1/2 readout est. (NCT06239272)
DESCRIPTION:Selinexor\, phase 1/2.\nStudy: NRSTS2021\, A Risk Adapted Study
  Evaluating Maintenance Pazopanib\, Limited Margin\, Dose-Escalated Radiat
 ion Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRS
 TS)\nEstimated primary completion: June 2034. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/selinexor#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06239272
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
